Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Canada Plans Parallel HTA And Marketing Authorization Reviews

Canada plans to run regulatory reviews and health technology appraisals in parallel for certain new medicines. This could mean some companies get their drugs listed on public health plans almost immediately upon market authorization, rather than having to wait for more than a year.

Canada Regulation

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Regulation BioPharmaceutical

Ontario Introduces Canada’s First Universal Youth Drug Program

Health authorities in Ontario, Canada, have become the first to offer a universal drug program offering younger patients access to free medicines. The move could be a small step towards eventually establishing a National Pharmacare Program across Canada.

Policy Reimbursement

Brazil’s New Patent Agreement Is “Real and Concrete Threat” To IP

An agreement between Brazil’s medicines regulator, ANVISA, and the National Institute of Industrial Property, INPI, aimed at clearly defining their respective roles in the patent application process could pose a threat to the patent system, say IPR experts.

BioPharmaceutical Intellectual Property

New Law Could Bring Surge in Clinical Trials to Brazil

Companies could find Brazil a more attractive place to conduct clinical trials thanks advances in digital healthcare and a new law that will cut bureaucracy and shorten approval timelines for trials.

Regulation Clinical Trials

ABPI Welcomes Amended Legislation On Curbing Excessive Unbranded Drug Prices

Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.

BioPharmaceutical United Kingdom
See All
Advertisement
UsernamePublicRestriction

Register